Selecting the Optimal Antithrombotic Regimen for Patients with Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2009 Aug 27

PMID 19707287

Authors

Shailja V Parikh

Ellen C Keeley

Affiliations

Soon will be listed here.

Abstract

The wide variety of anticoagulant and antiplatelet agents available for clinical use has made choosing the optimal antithrombotic regimen for patients with acute coronary syndromes undergoing percutaneous coronary intervention a complex task. While there is no single best regimen, from a risk-benefit ratio standpoint, particular regimens may be considered optimal for different patients. We review the mechanisms of action for the commonly prescribed antithrombotic medications, summarize pertinent data from randomized trials on their use in acute coronary syndromes, and provide an algorithm (incorporating data from these trials as well as risk assessment instruments) that will help guide the decision-making process.

References

Antman E, Cohen M, Bernink P, McCabe C, Horacek T, Papuchis G . The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA. 2000; 284(7):835-42. DOI: 10.1001/jama.284.7.835. View

Eagle K, Lim M, Dabbous O, Pieper K, Goldberg R, Van de Werf F . A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA. 2004; 291(22):2727-33. DOI: 10.1001/jama.291.22.2727. View

Steffel J, Luscher T . Novel anticoagulants in clinical development: focus on factor Xa and direct thrombin inhibitors. J Cardiovasc Med (Hagerstown). 2009; 10(8):616-23. DOI: 10.2459/JCM.0b013e32832edac0. View

Bittl J, Strony J, Brinker J, Ahmed W, Meckel C, Chaitman B . Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med. 1995; 333(12):764-9. DOI: 10.1056/NEJM199509213331204. View

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

Yusuf S, Mehta S, Chrolavicius S, Afzal R, Pogue J, Granger C . Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med. 2006; 354(14):1464-76. DOI: 10.1056/NEJMoa055443. View

Nutescu E, Spinler S, Wittkowsky A, Dager W . Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009; 43(6):1064-83. DOI: 10.1345/aph.1L194. View

. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N Engl J Med. 1996; 335(11):775-82. DOI: 10.1056/NEJM199609123351103. View

Antman E, Hand M, Armstrong P, Bates E, Green L, Halasyamani L . 2007 focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2008; 51(2):210-47. DOI: 10.1016/j.jacc.2007.10.001. View

10.

Gent M, Blakely J, Easton J, Ellis D, Hachinski V, Harbison J . The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet. 1989; 1(8649):1215-20. DOI: 10.1016/s0140-6736(89)92327-1. View

11.

Doyle B, Rihal C, Gastineau D, Holmes Jr D . Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice. J Am Coll Cardiol. 2009; 53(22):2019-27. DOI: 10.1016/j.jacc.2008.12.073. View

12.

Melloni C, Alexander K, Chen A, Newby L, Roe M, Allen LaPointe N . Unfractionated heparin dosing and risk of major bleeding in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008; 156(2):209-15. DOI: 10.1016/j.ahj.2008.03.023. View

13.

Foster C, Prosser D, Agans J, Zhai Y, Smith M, Lachowicz J . Molecular identification and characterization of the platelet ADP receptor targeted by thienopyridine antithrombotic drugs. J Clin Invest. 2001; 107(12):1591-8. PMC: 200194. DOI: 10.1172/JCI12242. View

14.

Vant Hof A, Berg J, Heestermans T, Dill T, Funck R, van Werkum W . Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. Lancet. 2008; 372(9638):537-46. DOI: 10.1016/S0140-6736(08)61235-0. View

15.

Marmur J, Poludasu S, Agarwal A, Manjappa N, Cavusoglu E . High-dose tirofiban administered as bolus-only during percutaneous coronary intervention. J Invasive Cardiol. 2008; 20(2):53-8. View

16.

Montalescot G, Wiviott S, Braunwald E, Murphy S, Gibson C, McCabe C . Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet. 2009; 373(9665):723-31. DOI: 10.1016/S0140-6736(09)60441-4. View

17.

Falk E, Shah P, Fuster V . Coronary plaque disruption. Circulation. 1995; 92(3):657-71. DOI: 10.1161/01.cir.92.3.657. View

18.

White H, Ohman E, Lincoff A, Bertrand M, Colombo A, McLaurin B . Safety and efficacy of bivalirudin with and without glycoprotein IIb/IIIa inhibitors in patients with acute coronary syndromes undergoing percutaneous coronary intervention 1-year results from the ACUITY (Acute Catheterization and Urgent.... J Am Coll Cardiol. 2008; 52(10):807-14. DOI: 10.1016/j.jacc.2008.05.036. View

19.

Clark N . Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res. 2008; 123 Suppl 1:S58-61. DOI: 10.1016/j.thromres.2008.08.005. View

20.

Keeley E, Boura J, Grines C . Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361(9351):13-20. DOI: 10.1016/S0140-6736(03)12113-7. View